How are the Results of Allogeneic Stem Cell Transplantation in Elderly Patients? A Single-center Experience
dc.contributor.author | Uysal, Ayse | |
dc.contributor.author | Erkurt, Mehmet Ali | |
dc.contributor.author | Kuku, İrfan | |
dc.contributor.author | Kaya, Emin | |
dc.contributor.author | Berber, İlhami | |
dc.contributor.author | Sarıcı, Ahmet | |
dc.contributor.author | Biçim, Soykan | |
dc.date.accessioned | 2024-08-04T19:42:31Z | |
dc.date.available | 2024-08-04T19:42:31Z | |
dc.date.issued | 2023 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | INTRODUCTION: In this study, we aimed to present allogeneic hematopoietic stem cell transplantation (allo-HCT) experience in elderly patients with hematological malignancy. METHODS: Thirty-five patients aged 60 years and older who underwent allo-HSCT between 2017 and 2021 were retrospectively analyzed. Patient's demographic/clinical features, and the outcomes of transplantation were reviewed. RESULTS: The median age was 63 (range, 60-74) years and 25 (77,1%) were male. Twenty-seven (60%) were diagnosed with AML, followed by MDS (n: 7, 20%). Twenty-three (65,8%) patients had intermediate, and 6 (17,1%) patients had a high hematopoietic cell transplantation-specific comorbidity index score. Karnofsky performance status of ? 90% was detected in 15 (42,9%) patients. Busulfan plus fludarabine plus anti-thymocyte globulin was used mainly as a reduced-intensity conditioning regimen, which was used in 18 (51,4%) patients. The median duration of neutrophil and platelet engraftments were 18 (range, 11-27) and 18 (range, 11-33) days, respectively. The median follow-up time was 4 months (range, 0-51), with the OS rate %14,2. The transplant-related mortality rate within the first 30 days after allo-HSCT was detected in 10 patients (28,6%) due to infection and/or GvHD. Response assessment could be performed in 25 (71,4%) patients after transplantation. The duration of PFS was 6 (range, 1-51) months in patients with response evaluation. The rate of PFS was 72% in 1 years and 5 (14,2%) patients were still alive with complete response at the last visit. DISCUSSION AND CONCLUSION: Reduced-intensity conditioning regimen has provided the important advantage in allo-HSCT, for elderly patients with hematological malignancies such as AML and MDS. | en_US |
dc.identifier.doi | 10.5505/aot.2023.70487 | |
dc.identifier.endpage | 113 | en_US |
dc.identifier.issn | 0304-596X | |
dc.identifier.issn | 2148-7669 | |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 106 | en_US |
dc.identifier.trdizinid | 1210544 | en_US |
dc.identifier.uri | https://doi.org/10.5505/aot.2023.70487 | |
dc.identifier.uri | https://search.trdizin.gov.tr/yayin/detay/1210544 | |
dc.identifier.uri | https://hdl.handle.net/11616/88391 | |
dc.identifier.volume | 56 | en_US |
dc.indekslendigikaynak | TR-Dizin | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | ACTA ONCOLOGICA TURCICA | en_US |
dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | How are the Results of Allogeneic Stem Cell Transplantation in Elderly Patients? A Single-center Experience | en_US |
dc.type | Article | en_US |